1. Introduction {#sec1}
===============

Histamine H~2~ receptor (HRH2) is a kind of Gs protein-coupled receptor, whose activation stimulates adenylyl cyclase and increases intracellular cAMP \[[@B33]\]. This type of histamine receptors was traditionally believed to be mainly expressed in upper gastrointestinal tract, heart, and central nervous system as well and mediated corresponding pathophysiological roles such as gastric muscular atrophy \[[@B35]\], ischemia-induced arrhythmia \[[@B16]\], and schizophrenia \[[@B15]\]. Besides the abovementioned classical places, HRH2 has long been recognized to be expressed in human mammary gland and breast cancer cells \[[@B9]\]. Furthermore, activation of HRH2 in breast cancer cells was reported to increase tumor proliferation \[[@B8], [@B10]\] and blocking HRH2 was suggested to improve disease-free survival in breast cancer patients \[[@B31]\]. Additionally, HRH2 expressed in other cells (e.g., fibroblasts) was also reported to mediate important effects on the epithelial-to-mesenchymal transition progress of breast cancer cells \[[@B32]\]. These findings strongly indicate that differential expression and function of HRH2 might be a risk factor of breast cancer.

Human HRH2 protein is encoded by*HRH2* gene, which is located in chromosome 5q35.2. Within*HRH2* gene, one single nucleotide polymorphism (SNP), rs2067474, has gained great attention from investigators today. This SNP results in a G1018A transition located in an enhancer element of*HRH2* gene promoter with a relevant allele frequency in diverse human populations according to previous reports \[[@B13]\] and also HapMap data (<http://www.hapmap.org/>). It was found that rs2067474 was significantly associated with risk of various diseases including cancer \[[@B35], [@B21]--[@B29]\] and presumed to induce changes in the expression of receptors \[[@B12]\]. Based on the notion that genetic variants (including histamine-related gene polymorphisms) contributed greatly to the development of breast cancer and also to the response to specific treatments and prognosis of the breast cancer patients \[[@B14]--[@B18]\], it is rational to hypothesize that rs2067474 might also be associated with breast cancer risk. However, as far as we know, no related investigations have been carried out.

Therefore, the goal of the present study was to demonstrate the relationship between rs2067474 of*HRH2* and breast cancer risk by using case-control method among Chinese Han population, hoping to provide further insights into the effect of HRH2 on the development of breast cancer.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

Two hundred and one Chinese Han women with breast cancer were recruited from our previous studies \[[@B17], [@B18]\], who were admitted to Kunming General Hospital of Chengdu Military Region between 2009 and 2014. Patients who had comorbidity, such as diabetes mellitus, hypertension, or any endocrine disorders, were excluded from the present study. We also recruited 238 unrelated, healthy Chinese Han women from the population of individuals referred for health examination in the same hospital as control group. All the participants in the control group had no known medical illness or hereditary disorders and were not taking any medications. Principal clinical characteristics, such as age at diagnosis, body mass index, and menopausal state, were obtained from the interviewer-administered health risk questionnaires. Menopausal status was defined as the date of last menses followed by 12 months of no menses. The clinicopathological variables and prognostic factors, that is, tumor size, histology, clinical stages, lymph node involvement, hormone receptor (including estrogen receptor and progesterone receptor) status, HER2 status, and p53 status, were obtained from the patients\' medical records. In particular, The HER2-positive status of all tumors was confirmed with the use of fluorescence in situ hybridization. The criteria for hormone receptor positive indicate that the proportion of tumor cells immunostained was more than 10%, and if the proportion of tumor cells immunostained was less than 10%, then it is negative. The histologic determinations, including tumor type and disease stage, were performed according to the World Health Organization criteria and the TNM classification system, respectively.

The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was reviewed and approved by the Ethical Committee of Kunming General Hospital of Chengdu Military Region. Statement of informed consent was obtained from all participants after full explanation of the procedure.

2.2. Genotyping Assay {#sec2.2}
---------------------

Sample preparation was as previously described \[[@B17], [@B18]\]. Briefly, the peripheral blood samples were collected into tubes containing ethylenediaminetetraacetic acid and stored at −80°C until analysis. Standard phenol--chloroform extraction method was used to extract genomic DNA from the whole blood. DNA concentration was measured by spectrometry (DU530 UV/VIS spectrophotometer, Beckman Instruments, Fullerton, CA, USA). Polymorphism of rs2067474 was genotyped by amplification-restriction and electrophoresis method as reported previously \[[@B12]\]. The primers used (according to the*HRH2* gene sequence Gene Bank Accession number AB023486) were as follows: forward 5′ACA GCC CGT GGC TAA GAA TGG3′ and reverse 5′AGA AGG GAG GCA GGA TGC AAG3′.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Statistical analyses in the present study were performed with SPSS 18.0 for Windows (PASW Statistics, SPSS Inc., Chicago, IL). The level of significance was set at *P* \< 0.05 (two-sided) for all tests. The SNP frequencies in both groups were tested for departure from Hardy--Weinberg Equilibrium (HWE). Student\'s *t*-test, analysis of variance (ANOVA), chi-square (Pearson\'s *χ* ^2^) test or Fisher\'s exact test, and unconditional multivariate logistic regression analysis adjusted for age, menopausal state, and body mass index (BMI) were used where necessary according to our previous reports \[[@B17], [@B18]\]. Odds ratios (ORs) with 95% confidential intervals (CIs) were used to assess the associations between genotypes and breast carcinoma risk or clinical variables.

3. Results {#sec3}
==========

3.1. Participants\' Characteristics {#sec3.1}
-----------------------------------

Descriptive clinical characteristics of both the breast cancer patients and health control subjects are listed in [Table 1](#tab1){ref-type="table"}, which shows no significant differences in age and the distribution of menopausal state (*P* = 0.381 and 0.120, resp.) between the cases and controls. However, the BMI values of these two groups exhibit statistical difference (*P* = 0.049). As for breast cancer cases, majority of patients were diagnosed with clinical stage I or II (78.6%) or with ductal invasive carcinoma (87.6%). Furthermore, 58.0% and 72.1% of the patients were lymph node metastasis carriers and positive for hormone receptors, respectively. There were 98 patients (48.8%) who were HER-negative (0) or HER-weak positive (1) carriers.

3.2. Distributions of rs2067474 Genotype and Allele between Breast Cancer Patients and Health Controls {#sec3.2}
------------------------------------------------------------------------------------------------------

The overall genotype and allele frequencies of rs2067474 in breast cancer cases and health controls are shown in [Table 2](#tab2){ref-type="table"}. The genotype distributions of rs2067474 in both groups were in the expected HWE (*P* = 0.152 for patients and 0.107 for controls, resp.). The minor allele frequency (MAF) of rs2067474 was 0.119 in case group and 0.166 in control group. We found no significant difference in the frequencies of genotypes (*P* = 0.174) or alleles (*P* = 0.054) between breast cancer patients and health controls according to univariate analysis ([Table 2](#tab2){ref-type="table"}). Considering that variables of age, menopausal state, and BMI may affect the development of breast cancer, we further performed multivariate regression analysis according to 3 different genetic models (i.e., dominant, recessive, and additive genetic models). However, as shown in [Table 3](#tab3){ref-type="table"}, we still did not observe any significant associations (*P* \> 0.05) between rs2067474 polymorphism and breast cancer risk after adjustment for age, menopausal state, and BMI in all of the 3 genetic models.

3.3. Association between rs2067474 Genotype Distribution and Clinicopathological Parameters in Patients with Breast Cancer {#sec3.3}
--------------------------------------------------------------------------------------------------------------------------

Then, we further analyzed the genotype distribution of rs2067474 according to different clinicopathological parameters. As shown in [Table 4](#tab4){ref-type="table"}, there were no statistical significances on the associations between genotype distribution of rs2067474 and nearly all selected clinicopathological parameters in the present study, except that the genotype distribution of rs2067474 was statistically correlated with the hormone receptor status of the present breast cancer patients (*P* = 0.016).

4. Discussion {#sec4}
=============

Histamine has been known to play many important roles in proliferation, differentiation, and epithelial-to-mesenchymal transition of many kinds of tumors including breast cancer \[[@B24]--[@B6]\], whose effects are mediated by 4 different types of histamine receptors (i.e., from H~1~ to H~4~ receptors), respectively. As a result, the 4 types of histamine receptor genes might all be candidate genes associated with breast cancer. However, recent work has paid much attention to the relationships between breast cancer and two newly discovered histamine receptors (i.e., H~3~ and H~4~ receptors) \[[@B25], [@B26]\]. Our previous studies also focused on these two histamine receptors and found that polymorphism of H~4~ receptor gene, but not H~3~ receptor gene, was associated with the risk and malignant degree of breast cancer in Chinese Han populations \[[@B17], [@B18]\] while for HRH2 no study focused on the relationship between its gene polymorphism and breast cancer so far. Therefore, elucidating this issue might provide better understandings of how HRH2 affects the development of breast cancer.

Among*HRH2* gene polymorphisms, we selected one SNP, rs2067474, in the present study as this SNP was widely studied and reported to be associated with many kinds of diseases \[[@B35], [@B21]--[@B12]\]. Furthermore, this SNP is located in an enhancer element of*HRH2* gene promoter and is very likely to affect the transcription and expression of HRH2 \[[@B13], [@B29], [@B12]\]. According to the present data, the MAF of rs2067474 in control group (0.166) was close to the allele frequency data of the previous studies on East Asian populations \[[@B35]\] and also HapMap CHB data (<http://www.hapmap.org/>). Furthermore, the genotype distributions of rs2067474 in both case and control groups were in HWE, which demonstrates that the case-control samples consist of a representative population for the study. However, we did not observe any significant associations between rs2067474 and breast cancer risk in the present study.

It should be mentioned that, although HRH2 was found to be widely expressed in many other cancer cells and was suggested to be related to their proliferation and differentiation \[[@B1], [@B2], [@B30]\], early clinical investigations regarding its relationship with breast cancer did not reach a consistent conclusion \[[@B5], [@B4]\]. This may partially be due to the interactive hormone promoting effect of the currently available HRH2 antagonists \[[@B27]--[@B22]\], which was very likely to mask the eventual HRH2 blocking effect of these HRH2 antagonists. Therefore, since genetic association investigation does not involve the application of any HRH2 antagonists, our present findings may be more persuasive regarding the direct effect of HRH2 on breast cancer compared with previous investigations.

An interesting finding of the present study is that the genotype distribution of rs2067474 was statistically associated with the hormone receptor status. The underlying mechanisms are unknown yet. Some early investigations have indicated that histamine and HRH2 were involved in the regulation of pituitary hormone secretion \[[@B28], [@B20]\], which, in turn, might affect the expressions of estrogen receptor or progesterone receptors in breast tissue cells. Future work is needed to elucidate this possibility.

In summary, to our best knowledge, this work is the first study addressing the relationship between*HRH2* gene polymorphism and risk of breast cancer. However, no statistical association was observed regarding rs2067474 in this study, which indicates that this*HRH2* gene polymorphism might not be a risk factor in the development of breast cancer in Chinese Han population.
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###### 

Characteristics of breast cancer patients and control participants.

                            Breast cancer (*n* = 201)   Control (*n* = 238)   *P*
  ------------------------- --------------------------- --------------------- ---------------
  Age (years)               46.5 ± 9.2                  47.2 ± 7.9            0.381^a^
  BMI (kg/m^2^)             23.1 ± 2.9                  22.6 ± 2.7            **0.049** ^a^
  Sex                                                                          
   Women                    201 (100%)                  238 (100%)            **---**
  Menopausal state                                                             
   Premenopausal            126 (62.7%)                 131 (55.0%)           0.120^b^
   Postmenopausal           75 (37.3%)                  107 (45.0%)           
  Tumor size (cm)                                                              
   ≤2.0                     44 (21.9%)                                         
   \>2.0                    157 (78.1%)                                        
  Histology                                                                    
   DIC                      176 (87.6%)                                        
   LIC                      9 (4.4%)                                           
   Others                   16 (8.0%)                                          
  Clinical stages                                                              
   I or II                  158 (78.6%)                                        
   III or IV                43 (21.4%)                                         
  Lymph node metastasis                                                        
   Node-negative            116 (58.0%)                                        
   Node-positive            85 (42.0%)                                         
  Hormone receptor status                                                      
   Negative                 56 (27.9%)                                         
   Positive                 145 (72.1%)                                        
  HER2 status                                                                  
   0-1                      98 (48.8%)                                         
   2-3                      103 (51.2%)                                        

BMI: body mass index, DIC: ductal invasive carcinoma, and LIC: lobular invasive carcinoma.

^a^ *P* values were calculated by Student\'s *t*-tests.

^b^ *P* values were calculated from two-sided chi-square test.

###### 

Frequency distributions of *HRH2* rs2067474 genotypes and allele and their associations with the risk of developing breast cancer.

  rs2067474   Breast cancer   Control      *P* ^a^   OR (95% CI)
  ----------- --------------- ------------ --------- ----------------------
  Genotype                                            
   GG         158 (78.6)      169 (71.0)   0.174     ---
   GA         38 (18.9)       59 (24.8)              
   AA         5 (2.5)         10 (4.2)               
  Allele                                              
   G          354 (88.1)      397 (83.4)   0.054     0.681 (0.463--1.003)
   A          48 (11.9)       79 (16.6)              

OR: odd ratio, CI: confidence interval, and Ref: reference category.

^a^ *P* values were calculated from two-sided chi-square tests.

###### 

Multivariate analysis for *HRH2* rs2067474 polymorphism and risk of breast cancer according to dominant, recessive, and additive genetic models.

              Dominant model                Recessive model               Additive model
  ----------- ----------------------------- ----------------------------- -----------------------------
  rs2067474   0.065; 0.660 (0.424--1.027)   0.275; 0.543 (0.182--1.625)   0.056; 0.696 (0.480--1.010)

OR: odd ratio; CI: confidence interval.

^a^ *P* values were calculated by logistic regression adjusted for age, menopausal state, and body mass index.

###### 

Correlations of clinicopathological parameters and *HRH2* rs2067474 polymorphism in patients with breast cancer.

                            rs2067474     *P*                        
  ------------------------- ------------- ------------ ------------- ---------------
  Age (years)               46.4 ± 9.2    47.1 ± 8.8   45.6 ± 12.8   0.878^a^
  BMI (kg/m^2^)                                                       
   ≥25                      33 (70.2%)    12 (25.5%)   2 (4.3%)      0.206^b^
   \<25                     125 (81.2%)   26 (16.9%)   3 (1.9%)      
  Menopausal state                                                    
   Premenopausal            102 (81.0%)   21 (16.7%)   3 (2.4%)      0.558^b^
   Postmenopausal           56 (74.7%)    17 (22.7%)   2 (2.7%)      
  Tumor size (cm)                                                     
   ≤2.0                     37 (84.1%)    5 (11.4%)    2 (4.5%)      0.203^b^
   \>2.0                    121 (77.1%)   33 (21.0%)   3 (1.9%)      
  Histology                                                           
   DIC                      137 (77.8%)   36 (20.5%)   3 (1.7%)      0.116^b^
   LIC                      8 (88.9%)     1 (11.1%)    0 (0.0%)      
   Others                   13 (81.3%)    1 (6.3%)     2 (12.5%)     
  Clinical stages                                                     
   I or II                  124 (78.5%)   30 (19.0%)   4 (2.5%)      1.000^b^
   III or IV                34 (79.1%)    8 (18.6%)    1 (2.3%)      
  Lymph node metastasis                                               
   Node-negative            89 (76.7%)    23 (19.8%)   4 (3.4%)      0.606^b^
   Node-positive            69 (81.2%)    15 (17.6%)   1 (1.2%)      
  Hormone receptor status                                             
   Negative                 45 (80.4%)    7 (12.5%)    4 (7.1%)      **0.016** ^b^
   Positive                 113 (77.9%)   31 (21.4%)   1 (0.7%)      
  HER2 status                                                         
   0-1                      81 (82.7%)    16 (16.3%)   1 (1.0%)      0.267^b^
   2-3                      77 (74.8%)    22 (21.4%)   4 (3.9%)      
  p53 status                                                          
   Negative                 41 (78.8%)    9 (17.3%)    2 (3.8%)      0.311^b^
   Positive                 62 (77.5%)    18 (22.5%)   0 (0.0%)      
   Undetermined             55 (79.7%)    11 (15.9%)   3 (4.3%)      

OR: odd ratio, CI: confidence interval, BMI: body mass index, DIC: ductal invasive carcinoma, LIC: lobular invasive carcinoma, *HER2*: human epidermal growth factor receptor, and p53: tumor protein 53.

^a^ *P* values were calculated by analysis of variance (ANOVA).

^b^ *P* values were calculated from two-sided chi-square tests or Fisher\'s exact tests.
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